RET (S904F)

RET · Variant type: point · HGVS: p.S904F

Drug response on this variant

#	Drug	Inhibition on variant	Residual	KISS
1	Alectinib	100.0%	0.0%	95.49
2	Pralsetinib	99.4%	0.6%	93.43
3	Selpercatinib	99.1%	0.9%	96.72
4	Nintedanib	98.5%	1.5%	90.23
5	Ponatinib	98.3%	1.7%	78.23
6	Tivozanib	97.7%	2.3%	92.42
7	Fedratinib	97.7%	2.3%	96.21
8	Lenvatinib	97.7%	2.3%	97.74
9	Brigatinib	97.5%	2.5%	82.96
10	Regorafenib	96.7%	3.3%	95.99
11	Tenalisib	96.6%	3.4%	97.98
12	Alpelisib	96.4%	3.6%	97.22
13	Entrectinib	96.3%	3.7%	93.69
14	Fostamatinib	95.7%	4.3%	96.74
15	Pazopanib	95.3%	4.7%	97.49
16	Gilteritinib	94.3%	5.7%	88.97
17	Cabozantinib	93.1%	6.9%	92.73
18	Vandetanib	87.7%	12.3%	95.74
19	Baricitinib	87.1%	12.9%	97.99
20	Sunitinib	86.8%	13.2%	91.73
21	Axitinib	86.5%	13.5%	93.23
22	Futibatinib	83.6%	16.4%	98.48
23	Dabrafenib	82.0%	18.0%	94.74
24	Sorafenib	80.2%	19.8%	96.72
25	Avapritinib	77.8%	22.2%	97.73

Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).

Drug	Variant inh	WT inh	Δ (variant − WT)
Alectinib	100.0%	97.8%	+2.2%
Pralsetinib	99.4%	100.0%	-0.6%
Selpercatinib	99.1%	100.0%	-0.9%
Nintedanib	98.5%	100.0%	-1.5%
Ponatinib	98.3%	100.0%	-1.7%
Tivozanib	97.7%	99.7%	-2.0%
Fedratinib	97.7%	99.9%	-2.2%
Lenvatinib	97.7%	98.8%	-1.2%
Brigatinib	97.5%	94.9%	+2.6%
Regorafenib	96.7%	98.7%	-2.1%
Tenalisib	96.6%	98.5%	-1.9%
Alpelisib	96.4%	99.6%	-3.2%
Entrectinib	96.3%	99.6%	-3.3%
Fostamatinib	95.7%	—	—
Pazopanib	95.3%	—	—
Gilteritinib	94.3%	100.0%	-5.7%
Cabozantinib	93.1%	97.5%	-4.5%
Vandetanib	87.7%	98.6%	-10.9%
Baricitinib	87.1%	—	—
Sunitinib	86.8%	97.2%	-10.5%
Axitinib	86.5%	—	—
Futibatinib	83.6%	97.7%	-14.1%
Dabrafenib	82.0%	—	—
Sorafenib	80.2%	94.0%	-13.7%
Avapritinib	77.8%	—	—

Cancer	Organ	Source
carcinoma_large_intestine	Large Intestine	ref

Loading…

Served from saifudeen2026@1.0.0 · API 0.1.0 · 14.1ms